Try our Advanced Search for more refined results
Life Sciences
-
March 25, 2026
Fecal Treatment Co. Says Ch. 11 Is Best Option To Sell Assets
Microbiome treatment developer Finch Therapeutics told a Delaware bankruptcy judge Wednesday that its lack of income or ability to collect on a patent judgment justified its Chapter 11 filing despite a lack of secured debts.
-
March 25, 2026
Judge Trims SEC Fraud Case Over Cancer Drug Claims
A Massachusetts federal judge greenlighted U.S. Securities and Exchange Commission claims against two of three former pharmaceutical executives accused of concealing from investors the U.S. Food and Drug Administration's "harsh critiques" about a cancer drug.
-
March 25, 2026
Insurer Need Not Cover Parkinson's Drug Antitrust Dispute
An insurer does not owe coverage in an antitrust suit accusing a pharmaceutical company of suppressing generic versions of the Parkinson's treatment Apokyn, a Maryland federal judge ruled, finding the dispute does not involve "securities claims" covered under the insurer's policy.
-
March 25, 2026
Biotech 'Lowballed' Landlord On Lease Exit, Suit Says
Biopharma company Werewolf Therapeutics has offered its Massachusetts landlord little more than 10 cents on the dollar to buy out the remainder of a lease for its lab space, even as the firm pays out departing executives and other creditors, according to a lawsuit brought in state court.
-
March 25, 2026
Dechert Adds Pauls Weiss Patent Partners In DC, NY
Dechert LLP has hired two Paul Weiss Rifkind Wharton & Garrison LLP lawyers who have backgrounds in life sciences and electrical engineering, the firm announced Tuesday.
-
March 25, 2026
Covington, Freshfields Advise On $6.7B Merck Oncology Deal
Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion.
-
March 24, 2026
Trump Admin Settles Suit Over Biden Social Media Collabs
The Trump administration on Tuesday agreed to bar three federal agencies from interfering with social media companies' content moderation, resolving a high-profile challenge to the Biden administration's efforts to combat the spread of misinformation in a case that went up to the U.S. Supreme Court.
-
March 24, 2026
Nicotine Pouch Maker To Refile FDA Suit In DC After Transfer
The maker and seller of Zone nicotine pouches on Tuesday dismissed its own lawsuit accusing the U.S. Food and Drug Administration of unfairly holding up a market application for its product, promising to refile in D.C. federal court after a Texas federal court transferred it to South Carolina federal court.
-
March 24, 2026
Agenus Escapes Investor Fraud Suit Over Cancer Drug
A Massachusetts federal judge on Tuesday tossed securities fraud claims against Agenus Inc., saying the biotech company did not conceal the risk that a colorectal cancer therapy it was developing might face roadblocks.
-
March 24, 2026
Drug Co. Atara Hit With Investor Suit Over FDA Denial
Drug company Atara Biotherapeutics Inc. has been hit with a proposed class action accusing it of harming investors by not disclosing certain manufacturing problems and research study deficiencies that made it unlikely the U.S. Food and Drug Administration would approve its new drug application.
-
March 24, 2026
Squires Institutes 6 Patent Reviews, Denies 15 Others
U.S. Patent and Trademark Office Director John Squires has granted six petitions seeking America Invents Act reviews of patents and rejected 15 others, according to his latest summary order listing his most recent decisions.
-
March 24, 2026
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP
Sarepta Therapeutics Inc. wants the full Federal Circuit to rethink a decision reviving a University of Pennsylvania gene therapy patent, saying a panel got its analysis of patent eligibility wrong.
-
March 24, 2026
ITC Says Hydrafacial Patent Infringed, But Won't Ban Imports
The U.S. International Trade Commission has found that an aesthetics medical device company infringed a Hydrafacial LLC skin treatment patent, but stopped short of enforcing a ban on imports.
-
March 24, 2026
CBP Frees Redesigned Smart Rings From Import Ban
U.S. Customs and Border Protection has lifted an import ban issued by the U.S. International Trade Commission on smart rings made by Ultrahuman, finding that a redesign cleared the product of infringing a patent held by Ouraring.
-
March 24, 2026
Fla. Judge Tosses Fired Reporter's Vaccine Suit Against PGA
A Florida federal judge has ruled in favor of the PGA Tour in a lawsuit brought by a reporter who claimed she was fired for not complying with COVID-19 protocols, saying she couldn't claim a religious exemption.
-
March 24, 2026
FTC Rejects Bids To Block Gender-Affirming Care Probe
A transgender medical care group and two healthcare trade organizations must turn over documents related to the group's claims made in their marketing and advertising for gender-affirming care for minors, the Federal Trade Commission ordered, denying the groups' motions to quash the agency's consumer protection investigation.
-
March 24, 2026
6 Firms Guide Gilead's $2.2B Autoimmune Drug Play
Gilead Sciences Inc. has agreed to acquire privately held Ouro Medicines for up to $2.175 billion and is in advanced discussions with Galapagos NV on a potential research and development collaboration on the assets, according to an announcement late Monday from Gilead.
-
March 24, 2026
Alston & Bird Hires Ex-FDA Deputy Counsel From DLA Piper
Alston & Bird LLP announced on Tuesday it has hired a longtime government lawyer and former DLA Piper attorney to assist with the firm's work helping companies handle FDA compliance issues and regulatory disputes over medical products.
-
March 24, 2026
FTC To Mull Caremark Deal In PBM Insulin Pricing Case
Federal Trade Commission staffers have asked to let the agency's commissioners consider a potential settlement with Caremark in a case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes, following a recent deal with Express Scripts.
-
March 24, 2026
Beasley Allen Says NJ Justices Review Of Talc DQ 'Essential'
Beasley Allen urged the New Jersey Supreme Court to hear its appeal of a lower court's decision to disqualify it from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, arguing that the court's immediate review of the interlocutory order is "essential."
-
March 24, 2026
Ohio Justices Likely Split On Trans Care Restrictions
The Ohio Supreme Court appeared split Tuesday as to whether a new state law banning gender-affirming care for minors trumps a decade-old healthcare freedom provision passed by voters that says state laws can't block a patient from obtaining healthcare.
-
March 24, 2026
Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias
A researcher and pharmaceutical executive brought in to help "right the ship" at an Ipsen Pharmaceuticals subsidiary says after a change in management, she was subjected to gender, age and racial bias and then fired.
-
March 24, 2026
Justices Won't Review Class Cert. In Diabetes Drug Risk Case
The U.S. Supreme Court has declined to review whether a federal court can certify a class of third-party payors who claim drugmakers hid the cancer risks of an anti-diabetes drug.
-
March 23, 2026
CooperSurgical Fights Docs Request In Embryo Loss Suit
Fertility company CooperSurgical Inc. is pushing back against a bid to compel the release of internal financial and other records in litigation brought by a couple who claims the company negligently destroyed their embryos with its recalled culture media, calling the request overly broad.
-
March 23, 2026
Amarin Tells Justices Hikma Drug Patent Appeal Threatens IP
Amarin Pharma Inc. has urged the U.S. Supreme Court to uphold a decision that it plausibly alleged that generics maker Hikma Pharmaceuticals USA Inc. encouraged infringement of patents on the heart drug Vascepa, saying a reversal "would dramatically dilute intellectual property protection throughout the nation."
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
When Trade Secret Litigation And Criminal Law Collide
An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.
-
Opinion
PTAB Needs Reform To Protect Inventors From Larger Cos.
The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.
-
FDA User Fee Talks Offer Clues On Upcoming Reforms
As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.
-
Moderna Case Highlights Overlooked Hurdle In Biopharma IP
The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.
-
FDA Framework For Personalized Therapies Raises Questions
The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.
-
Emissions Permits May Not Override Pollution Exclusions
Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.
-
5 Tips For Navigating Your Firm's All-Attorney Summit
Excerpt from Practical Guidance
Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.
-
Series
Coaching Soccer Makes Me A Better Lawyer
Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.
-
Series
Law School's Missed Lessons: The Human Element
Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.
-
Avoid The Unexpected When Drafting License Agreements
The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.
-
CMS Healthcare Enforcement Initiatives May Cause Disruption
The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
What New Animal Welfare Enforcement Push Means For Cos.
The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.